VX661

CAS No. 1152311-62-0

VX661( Tezacaftor )

Catalog No. M10537 CAS No. 1152311-62-0

VX-661 is a second F508del CFTR corrector and is believed to help CFTR protein reach the cell surface. Phase 2.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 43 In Stock
5MG 68 In Stock
10MG 113 In Stock
25MG 201 In Stock
50MG 324 In Stock
100MG 478 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    VX661
  • Note
    Research use only, not for human use.
  • Brief Description
    VX-661 is a second F508del CFTR corrector and is believed to help CFTR protein reach the cell surface. Phase 2.
  • Description
    VX-661 is a second F508del CFTR corrector and is believed to help CFTR protein reach the cell surface. Phase 2.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Tezacaftor
  • Pathway
    Apoptosis
  • Target
    CFTR
  • Recptor
    VFTR
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    1152311-62-0
  • Formula Weight
    520.5
  • Molecular Formula
    C26H27F3N2O6
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 100 mg/mL (192.12 mM)
  • SMILES
    O=C(C1(C2=CC=C(OC(F)(F)O3)C3=C2)CC1)NC4=CC5=C(N(C[C@@H](O)CO)C(C(C)(C)CO)=C5)C=C4F
  • Chemical Name
    (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Pettit RS, Fellner C. P T. 2014 Jul;39(7):500-12. Veit G, et al. Sci Transl Med. 2014 Jul 23;6(246):246ra97.
molnova catalog
related products
  • CFTR corrector 4

    CFTR corrector 4 is a potent and orally available transmembrane conductance regulator (CFTR) for cystic fibrosis and is a potent (R,R) type active enantiomer.

  • FDL169

    FDL-169 is a novel and potent CFTR (Cystic fibrosis transmembrane conductance regulator) corrector for treating cystic fibrosis (CF) patients who carry the F508del mutation.

  • Nesolicaftor

    PTI-428 specifically enhances cystic fibrosis transmembrane conductance regulator protein synthesis.